To view this email as a web page, click here.
 
NPs and PAs in Dermatology
 
COMMENTARY
 
Biologics and SK treatments
image description here In this month's Clinical Considerations, we take a look at dupimulab, tips for choosing the right biologic and treatments for seborrheic keratoses.

Read Joe Gorelick's takeaways.
For more information on the DERM2017 meeting visit www.DermNPPA.org.
 
CLINICAL CONSIDERATIONS
 
New therapeutic option
Long-term data for dupilumab in atopic dermatitis reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug's breakthrough status, according to experts.
Learn more.
 
Biologic class differentiators
Dermatology experts offer insight into differentiating factors among TNF-alpha inhibitors, the IL 12/23 antagonist, IL 17 inhibitors and an oral option that carry considerations for managing certain patients.
Learn more.
 
SKs concern patients
A recent study suggests patients are bothered by seborrheic keratoses and are inclined to want the lesions removed.
Learn more.
 
In case you missed it
 
Abatacept: Pricey, but Effective
image description here The approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.

Learn more.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.